Zydus Cadila

Go Back

Zydus Cadila

  • Oldest players in the Indian formulations market for several years
  • The group posted revenues of Rs 6,300 (US$ 1.02 billion) crores in FY13
  • Became a billion dollar company in FY11
  • Declared as the 'Emerging Company of the Year' by the Economic Times Awards for Corporate Excellence 2010
  • Only Indian pharma company to launch its own patented NCE - Lipaglyn

Zydus Cadila is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain. With a core competence in the field of healthcare, Zydus Cadila provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to wellness products. Zydus is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world's first drug to be approved for the treatment of diabetic dyslipidemia.

Source: http://www.zyduscadila.com/index.html

Zydus Cadila: Dedicated to life

2014 Mr Pankaj R Patel, Chairman and MD, Zydus Cadila was conferred the India Innovator Award 2013
2013 Zydus pioneers a breakthrough with Lipaglyn, India's first NCE to reach the market
2007 Zydus Cadila, the first to launch revolutionary anti-obesity drug Slimona in India
1995 Posted a turnover of Rs 250 crore (US$ 40.52 million)
1952 Zydus Cadila started opertaion

Updated: November, 2014

Biotechnology
India is ranked 12th in the world in biotech and third in Asia-Pacific.
x IBEF : India Brand Equity Foundation